Phase II Study of Trimetrexate in Malignant Melanoma: a National Cancer Institute of Canada Clinical Trials Group Study
Overview
Overview
Journal
Invest New Drugs
Publisher
Springer
Specialty
Oncology
Date
1990 Feb 1
PMID
2140563
Citations
1
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate. No responses were seen in 18 patients. We did not find trimetrexate given as described to be effective in metastatic malignant melanoma.
Citing Articles
Walling J Invest New Drugs. 2005; 24(1):37-77.
PMID: 16380836 DOI: 10.1007/s10637-005-4541-1.
References
1.
Fanucchi M, Walsh T, Fleisher M, Lokos G, Williams L, Cassidy C
. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res. 1987; 47(12):3303-8.
View
2.
Eisenhauer E, Zee B, Pater J, Walsh W
. Trimetrexate: predictors of severe or life-threatening toxic effects. J Natl Cancer Inst. 1988; 80(16):1318-22.
DOI: 10.1093/jnci/80.16.1318.
View
3.
Richter Jr W, McCormack J
. Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminiquinazolines and related compounds. J Med Chem. 1974; 17(9):943-7.
DOI: 10.1021/jm00255a007.
View
4.
Kamen B, Eibl B, Cashmore A, BERTINO J
. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol. 1984; 33(10):1697-9.
DOI: 10.1016/0006-2952(84)90298-3.
View